Rare / Orphan Disease
🧬

ATTR Amyloidosis

ATTR (transthyretin) amyloidosis is a rare, progressive disease where the TTR protein misfolds and deposits as amyloid fibrils in the heart and peripheral nerves. RNA interference therapies have dramatically improved outcomes — but average diagnostic delay is 4+ years.

An estimated 150,000+ Americans have ATTR amyloidosis. Wild-type ATTR (no gene mutation) affects primarily men over 65 with heart failure. Hereditary ATTR (hATTR) can strike at any age and affects both heart and nerves.

📡 NIH · CDC · FDA · ClinicalTrials.gov 🔔 Get Alerts
📊 ATTR Amyloidosis by the Numbers
150K+
estimated US patients
4 yrs
avg time to diagnosis
3
RNA-based therapies approved
500K
annual cost of some treatments ($)
🔄 Myth vs. Fact
❌ Myth

"ATTR amyloidosis is always hereditary."

👆 Tap to see the truth

✅ Fact

Wild-type (non-hereditary) ATTR is the more common form and affects mainly men over 65. It is NOT genetic — misfolded protein deposits increase with age. Many heart failure patients over 65 have undiagnosed wild-type ATTR.

👆 Tap to flip back

❌ Myth

"ATTR amyloidosis is a death sentence."

👆 Tap to see the truth

✅ Fact

RNA interference drugs like Amvuttra and Onpattro can reduce TTR protein production by 80%+, halting or reversing disease progression. Early treatment dramatically changes prognosis.

👆 Tap to flip back

❌ Myth

"ATTR only affects the heart."

👆 Tap to see the truth

✅ Fact

ATTR deposits affect the heart, peripheral nerves, GI tract, and soft tissues. The hereditary form particularly causes painful neuropathy. Patients often see multiple specialists before anyone connects the dots.

👆 Tap to flip back

❌ Myth

"ATTR is too rare to test for in heart failure patients."

👆 Tap to see the truth

✅ Fact

Studies show 13% of heart failure patients with preserved ejection fraction may have undiagnosed ATTR. A simple DPD/PYP nuclear scan is non-invasive and highly accurate.

👆 Tap to flip back

Did You Know?
A simple nuclear scan (DPD or PYP scintigraphy) can now diagnose cardiac ATTR non-invasively — no biopsy needed.
The Val30Met (p.Val50Met) mutation in the TTR gene is the most common cause of hereditary ATTR and is particularly prevalent in Portugal, Sweden, Brazil, and Japan.
African Americans have a 3–4% carrier frequency for the Val122Ile TTR mutation — a form of ATTR that causes heart disease and is dramatically underdiagnosed.
Onpattro (patisiran), approved in 2018, was the first RNA interference drug ever approved by the FDA.
Amvuttra requires only one injection every 3 months — vs. Onpattro's IV infusion every 3 weeks.
🍩 Breakdown by Type
60% Wild-type
60% Wild-type ATTR (acquired)
40% Hereditary ATTR
📅 Disease Progression
Years 1–2
Early Symptoms
Polyneuropathy (numbness, tingling in hands/feet), exertional dyspnea, carpal tunnel. Often attributed to diabetes or aging.
Years 2–5
Diagnostic Odyssey
Seen by neurologists, cardiologists, rheumatologists separately. Rarely connected as same disease. Average: 4 specialists before diagnosis.
Year 3–5 avg
Diagnosis
Nuclear scintigraphy, genetic testing, or biopsy confirms ATTR. Specialist at amyloidosis center critical for treatment guidance.
First injection/infusion
Treatment Initiated
RNA interference (Amvuttra, Onpattro) or antisense (Wainua) reduces TTR 80%+. Stabilizers (tafamidis) for cardiac ATTR. Long-term management.

"ATTR amyloidosis affects 150,000+ Americans — and 13% of older heart failure patients may have it undiagnosed."

💊 FDA-Approved Treatments for ATTR Amyloidosis

There are currently 4 FDA-approved disease-modifying therapies for ATTR Amyloidosis. These are targeted treatments — not just symptom management.

FDA Approved 2022

Amvuttra

vutrisiran

Company Alnylam Pharmaceuticals
Drug type RNA Interference (RNAi)
Approved for hATTR amyloidosis with polyneuropathy in adults
List price ~$490,000/year

💚 Financial Assistance Available

Alnylam's Assist360 program provides access support including co-pay assistance and free drug for eligible uninsured patients. Quarterly subcutaneous injection.

FDA Approved 2018

Onpattro

patisiran

Company Alnylam Pharmaceuticals
Drug type RNA Interference (RNAi)
Approved for hATTR amyloidosis with polyneuropathy in adults
List price ~$450,000/year

💚 Financial Assistance Available

Alnylam's Assist360 program provides comprehensive support. Medicare Part B typically covers Onpattro. First RNA interference drug ever approved by FDA.

FDA Approved 2023

Wainua

eplontersen

Company Ionis / AstraZeneca
Drug type Antisense Oligonucleotide
Approved for Adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
List price ~$490,000/year

💚 Financial Assistance Available

Ionis and AstraZeneca patient support services available for eligible patients. Monthly subcutaneous self-injection — no infusion center required.

FDA Approved 2019

Vyndaqel / Vyndamax

tafamidis

Company Pfizer
Drug type Small Molecule Oral
Approved for ATTR cardiomyopathy (both wild-type and hereditary) in adults
List price ~$225,000–$268,000/year

💚 Financial Assistance Available

Pfizer RxPathways provides co-pay assistance and patient support. TTR stabilizer (not RNA-based) — oral daily pill. First approved therapy specifically for ATTR cardiomyopathy.

⚠️ High-cost drugs: insurance navigation matters

These treatments require prior authorization from your insurer. Most commercial insurance plans cover them with co-pay assistance programs. Medicare and Medicaid coverage varies by state and therapy. Ask your specialist's office for a patient navigator or specialty pharmacy partner — they handle PA processes daily.

⏱️ Average diagnostic delay: 4+ years — don't wait for things to get worse

Just diagnosed with ATTR amyloidosis? What to do first.

A diagnosis can feel overwhelming. Here's what patients and specialists say makes the biggest difference in the weeks after diagnosis.

🧬
1

Get TTR genetic testing — even if you're older

Whether you have hereditary or wild-type ATTR has major implications for your family and treatment. A simple blood test checks for TTR gene mutations. If you have hereditary ATTR, first-degree relatives should consider carrier testing.

🏥
2

Seek an amyloidosis specialist center

ATTR is managed best at centers with dedicated amyloidosis expertise — cardiologists and neurologists who see many ATTR patients. The Amyloidosis Research Consortium (arci.org) maintains a directory. General cardiologists may be unfamiliar with ATTR treatment nuances.

💉
3

Understand your treatment options

For hereditary polyneuropathy ATTR: Amvuttra, Onpattro, or Wainua are RNA-based therapies that reduce TTR production by 80%+. For wild-type or hereditary cardiac ATTR: tafamidis (Vyndaqel/Vyndamax) stabilizes TTR to prevent misfolding. The choice depends on your specific manifestation. Many patients have both cardiac and neurologic involvement.

💰
4

Engage manufacturer patient support programs early

Alnylam's Assist360 program and Ionis's patient support can significantly reduce out-of-pocket costs for commercially insured or uninsured patients. These drugs list at $450K-$500K/year — engagement with specialty pharmacy and payer prior authorization is essential.

👥
5

Connect with the ATTR community

Rare Diseases Clinical Research Network and Amyloidosis Support Groups (amyloidosissupport.org) provide peer support and disease information. Clinical trials are also actively enrolling — ask your specialist about eligibility.

🔔 FREE ALERTS + PERSONALIZED UPDATES

Get ATTR Amyloidosis Research Updates — Personalized to Your Situation

Weekly updates from NIH, FDA, and ClinicalTrials.gov. Tell us a little about your situation and we'll filter what's most relevant for you. Free. No spam. Unsubscribe anytime.

Only email is required. By subscribing you agree to receive updates from My Sugar Pill. We never sell your data. Privacy policy.

Community Feed

What patients and caregivers are saying about ATTR Amyloidosis

View All →
⏳
Loading community posts…
Have something to share?

Join the ATTR Amyloidosis community discussion on /pulse — share your experience, ask questions, or post research you've found.

Go to Pulse →

📰 Latest ATTR Amyloidosis Research & News

🧬

Research updates coming soon

Our pipeline pulls daily from NIH, CDC, and FDA. Check back tomorrow for the latest ATTR Amyloidosis research.

About this content

Sourced from U.S. government health agencies (NIH, CDC, FDA) and ClinicalTrials.gov. Summaries written in plain English for a 55+ audience. Always consult your doctor before making healthcare decisions. My Sugar Pill does not provide medical advice.

About My Sugar Pill · No sponsored content · No data selling · Free, always.

❓ Frequently Asked Questions About ATTR Amyloidosis

Answers in plain English — no jargon. Based on what patients, caregivers, and newly diagnosed people actually ask.